ArticleBreast cancer (Tokyo, Japan)2023

ER-/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor.

Christine Song et al.PubMed ↗Publisher ↗

No numbers read from the abstract.